


The Spacefarer Phenome


An AI-orchestrated, repurposing-first computational drug-discovery pipeline for astronaut resilience.



SYS_RUN: 2026-07-12 |
BUILD: GRCh38 |
STATUS: FROZEN

Microgravity as a Catalyst for Biological Ageing


The Stressor



Microgravity unloading drives osteoclast-biased bone remodelling.

- Result: ~1-2% areal bone mineral density (BMD) loss per month in astronauts.

The Overlap with Ageing




This aerospace stressor maps directly to terrestrial ageing hallmarks:

- Stem-cell exhaustion (MSC to osteoblast)
- Cellular senescence (osteocyte SASP)
- Altered intercellular communication (RANKL/WNT)

The Mission Objective: Mine human genetic variation to discover protective alleles, causally validate their effects, and repurpose small molecules to safely mimic their protection.

The Pipeline Architecture: A Cheap-to-Expensive Filtration Funnel



Strict Governance and Provenance by Default

Agentic Harness



Pre-registration

All statistical thresholds and multiplicity denominators (e.g., `N_targets = 33`) are frozen in a version-controlled `params.yaml` prior to execution. No relaxing rules for borderline hits.



Contract-First Handoffs

Agents communicate exclusively through schema-validated JSON envelopes. No free-text guessing. Every stage is swappable and re-runnable.



Immutable Provenance


Every artifact generates a run-manifest tracking database versions, API endpoints, random seeds, and SHA-256 hashes.

Phase 1: The Genetics Engine & Target Discovery

Using heel estimated BMD (N=426,824) as the primary exposure to find independent instruments.

Classic Mendelian Randomisation 	Drug-Target (cis-MR) 
The Core Question	The Core Question
Does a modifiable exposure (trait) cause the outcome?	Does pharmacologically modulating a specific target change the outcome?
Biological Precision	Biological Precision
Instruments: Genome-wide SNPs. Biology: Distal, prone to pleiotropy. Use: Triangulating biological pathways.	Instruments: cis-QTL variants only. Biology: Proximal (variant → protein → phenotype). Use: The primary discovery engine for druggability.

The Crucial Safety Gate: Phenome-Wide Liability Screening



Only targets clearing these phenome-wide hurdles unlock the structural GPU budget.

Pilot Execution: The Genetics Verdict

INPUT: 33 FROZEN DRUGGABLE TARGETS

STATUS: 26 lacked reachable large-N cis-eQTLs.

STATUS: 7 testable targets processed.

EVALUATING CAUSALITY GATE...


[PALE RED HIGHLIGHT] RESULT: All 7 failed strict causality (Bonferroni $\alpha = 1.52e-03$; coloc.abf PP.H4 < 0.8).



0 / 33 Targets
Advanced

- **The Validation:** The eBMD→fracture positive control passed strongly ($p = 1.85e-44$), proving the MR machinery works perfectly.
- **The Conclusion:** A triumphant instrument-limited negative. The funnel successfully rejected weak signals rather than relaxing pre-registered thresholds to invent a false positive.

The CTSK Anchor: Advancing the Structural Engine



The Strategy

To validate Stages 5-7 (Structure, Docking, MD) independently of the genetics negative, the pipeline advanced Cathepsin-K (CTSK) as a pre-specified small-molecule anchor.


Biological Grounding

CTSK is the dominant osteoclast collagenase. Human loss-of-function causes **pseudotumor** (high bone density), explicitly validating inhibition as the required therapeutic direction to counteract spaceflight bone loss.

Structural Preparation & Docking Consensus

Structural Security

Target structure confirmed via 5TDI (X-ray 1.4 Å) and AF2 model. Pocket confidence is exceptionally high (pLDDT 97.56). Sub-Ångström concordance (0.27 Å RMSD) between experimental and predicted pockets.



Docking Gate (Gate D)

Evaluated using a two-method consensus (Vina CPU + Boltz-2 GPU).

Redock Control

Odanacatib control successfully redocked at 1.026 Å (well under the strict < 2.0 Å requirement).

~1,155 library compounds

24-compound shortlist

Molecular Dynamics Verdict: Designing Away from Liability


The CV Caveat: Odanacatib (control) was flagged at Gate C for realised **Phase-3 cardiovascular/stroke liability**. The **directive: find a structurally distinct alternative**.

Gate-C FLAG: CV Liability

Odanacatib (The Control)

Confirms the MD protocol.

RMSD plateau 1.60 Å




Chemotype-Distinct

CHEMBL2164674 (The Lead)

Pipeline identified a physically stable candidate avoiding the control's liability space.

RMSD plateau 0.99 Å

Tanimoto similarity:
0.165




High-Value Filtration: The \$41.06 Blueprint

\$41.06 Total Compute Spend

Compute Economy

Stages 0 through 4 (Genetics, Safety, Druggability) utilised CPU and open APIs, costing \$0.00.

— CPU focus



\$41.06 Spent (3.2%)

Unused Budget (\$1,238.94)

Strategic Spend

GPU compute was exclusively unleashed on pre-validated survivors. Stage 6 (Docking) utilised \$2.02. Stage 7 (MD) utilised \$39.04.

— GPU focus

Total ROI

A causally-assessed genome, phenome-wide safety screen, and MD-validated compound shortlist executed for just 3.2% of the total available compute budget.

The Artifact

The Spacefarer Phenome provides a fully pre-registered, contract-driven, and safety-vetoed methodology for discovering physiological countermeasures.



Apache-2.0 (Code)

CC-BY-4.0 (Data/Report)

Open Science

Fully auditable via immutable SHA-256 run-manifests, guarding against subjective post-hoc adjustments.

The Future

A scalable, AI-orchestrated foundation ready to map the genomic frontier of human resilience in space.